Abatacept in Immune Checkpoint Inhibitor Myocarditis Trial
Phase 3
390
about 4.8 years
18+
29 sites in CA, DC, FL +18
About this study
This trial is testing whether abatacept, as compared to placebo, reduces major adverse cardiac events (MACE) in adults hospitalized with myocarditis caused by immune checkpoint inhibitors. MACE includes cardiovascular death, sudden cardiac arrest, cardiogenic shock, significant arrhythmias, or incident heart failure.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Abatacept plus
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
abatacept
injection, intravenous
Primary: Major adverse cardiac events
Secondary: Other immune-related adverse events between the two groups
Oncology